Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for acute and chronic diseases with high unmet medical need, particularly in neurology and nephrology. The company’s core focus is on leveraging recombinant protein therapeutics derived from human tissue kallikrein-1 (KLK1) biology to address vascular dysfunction, inflammation, and organ damage. DiaMedica operates within the biotechnology and pharmaceutical research and development industries.
The company’s primary product candidate is DM199, a recombinant form of human KLK1, which represents its principal revenue driver potential, as DiaMedica currently generates no commercial product revenue. DiaMedica is positioned as a niche innovator targeting conditions where existing therapies are limited or ineffective, such as acute ischemic stroke and chronic kidney disease. The company was founded in 2000, originally focused on diabetes-related technologies, and later evolved through strategic refocusing and acquisitions into a therapeutics-oriented biotech company centered on KLK1 biology.
Business Operations
DiaMedica’s operations are centered on research and development, with activities spanning preclinical studies, clinical trials, regulatory strategy, and intellectual property management. The company operates as a single reportable segment focused on the development of DM199, which is being evaluated in multiple clinical indications. Key development programs include acute ischemic stroke and chronic kidney disease, where DM199 is intended to improve microcirculatory blood flow and reduce tissue damage.
The company conducts clinical trials primarily through contracted clinical research organizations and maintains manufacturing relationships for biologics production rather than owning large-scale manufacturing facilities. DiaMedica operates in both domestic and international settings, with clinical trial activity conducted in North America and Europe. The company does not currently report material revenue from partnerships, and its operations are funded primarily through equity financing and public offerings.
Strategic Position & Investments
DiaMedica’s strategic direction is focused on advancing DM199 through mid- to late-stage clinical development while preserving capital efficiency. Growth initiatives include expanding the clinical indications of DM199 and pursuing regulatory pathways that could accelerate approval in high-need patient populations. The company has made targeted investments in clinical trial expansion rather than broad acquisitions, reflecting its single-asset development strategy.
The company does not maintain a diversified portfolio of subsidiaries or marketed products; instead, it concentrates resources on maximizing the value of its core biologic asset. DiaMedica is involved in emerging therapeutic approaches related to vascular protection and inflammation modulation, positioning DM199 as a potential first-in-class therapy in its targeted indications. Any future partnerships or licensing arrangements remain contingent on clinical outcomes, and publicly available sources indicate no completed transformative acquisitions to date.
Geographic Footprint
DiaMedica Therapeutics is headquartered in Minneapolis, Minnesota, United States, and its corporate, executive, and research management functions are based there. The company’s operational footprint is relatively lean, consistent with a clinical-stage biotechnology firm, and does not include extensive physical infrastructure outside its headquarters.
Despite its limited physical presence, DiaMedica maintains an international operational influence through global clinical trial execution. The company has conducted or planned studies across North America and Europe, engaging investigators, regulatory agencies, and service providers in multiple countries. Its global exposure is primarily research-driven rather than commercial, as it has not yet launched products in any market.
Leadership & Governance
DiaMedica is led by an experienced management team with backgrounds in biotechnology, pharmaceuticals, and clinical development. The leadership emphasizes disciplined capital management, clinical rigor, and a focused strategy centered on advancing DM199 toward regulatory approval. Governance follows standard public company practices, with oversight provided by an independent board of directors.
Key executives include:
- Rick Paulson – President and Chief Executive Officer
- Ted Kazarians – Chief Financial Officer
- Michael J. McMurray – Chief Medical Officer
- Arne L. Swanson – Chief Development Officer
- Nick Drozdowski – Vice President, Corporate Development
The leadership team’s strategic vision is centered on creating shareholder value by addressing serious diseases with limited treatment options through scientifically differentiated biologic therapies.